Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Status:
Completed
Trial end date:
2015-01-07
Target enrollment:
Participant gender:
Summary
This pilot, phase I trial studies the side effects and best dose of bortezomib in treating
patients with acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma that has come
back or has not responded to treatment. Bortezomib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.